Posted by Michael Wonder on 16 Sep 2021
BioCryst’s HAE med Orladeyo wins NICE nod
16 September 2021 - BioCryst’s Orladeyo (berotralstat) has received a positive recommendation from NICE for preventing recurrent attacks of hereditary angioedema in people aged 12 years and older.
In its draft guidance, NICE has recommended the treatment for people who have at least two attacks per month.
Orladeyo treatment should be stopped if the number of attacks per month does not reduce by at least 50% after three months of use.
